HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial

Published:2024-08 Issue:8 Volume:11 Page:e508-e521
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Wohl David A,Spinner Christoph D,Flamm Jason,Hare C Bradley,Doblecki-Lewis Susanne,Ruane Peter J,Molina Jean-Michel,Mills Anthony,Brinson Cynthia,Ramgopal Moti,Clarke Amanda,Crofoot Gordon,Martorell Claudia,Carter Christoph,Cox Stephanie,Hojilla J Carlo,Shao Yongwu,Das Moupali,Kintu Alexander,Baeten Jared M,Grant Robert M,Mounzer Karam,Mayer Kenneth

Funder

Gilead Sciences Inc

Publisher

Elsevier BV

Reference32 articles.

1. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men;Grant;N Engl J Med,2010

2. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial;Mayer;Lancet,2020

3. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial;Ogbuagu;Lancet HIV,2021

4. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report;Hoornenborg;Lancet HIV,2017

5. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial;Delany-Moretlwe;Lancet,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reassuring long-term safety, resistance, and efficacy data for two daily formulations of PrEP;The Lancet HIV;2024-08